This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial (DISC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Steven Messe, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00647998
First received: March 27, 2008
Last updated: May 1, 2017
Last verified: May 2017
March 27, 2008
May 1, 2017
January 2008
July 2010   (Final data collection date for primary outcome measure)
Death or Neurologic Disability, Defined as an National Institutes of Health Stroke Scale (NIHSS)>4 or American Spinal Injury Association (ASIA) Lower Extermity Motor Score <25 [ Time Frame: Discharge from the hospital ]
The NIHSS is a validated quasi-ordinal measure of stroke severity. An NIHSS >4 is generally considered moderate or severe. The ASIA Lower Extremity Motor Score is a cumulative total of assessments of strength in 5 muscles in each leg, using the Medical Research Council 0-5 stroke score. ASIA score < 25 is associated with impaired ambulation.
Death or Neurologic Disability, Defined as an NIHSS>4 or ASIA<25 [ Time Frame: Day 30 ]
Complete list of historical versions of study NCT00647998 on ClinicalTrials.gov Archive Site
  • CSF S100beta [ Time Frame: 48 hours ]
    Cerebrospinal fluid S100beta level
  • Hemoglobin [ Time Frame: 24 hours post-surgery ]
  • CSF Markers of Ischemia [ Time Frame: 24 hours ]
  • Hemoglobin [ Time Frame: Day 7, day 30 ]
Not Provided
Not Provided
 
The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial
Phase 2 Dose Finding Trial of Prophylactic Darbepoetin Alfa to Improve Outcomes From Ischemic Complications of Surgery
Numerous neuroprotectants have been effective when given prior to ischemic stroke in animals, yet they have all have failed when given after ischemic stroke in humans. A novel approach to ischemic neuroprotection is needed. Many patients who undergo cardiac, vascular, and neurosurgical procedures develop ischemic central nervous system (CNS) complications. These high risk surgeries present a unique opportunity to administer neuroprotectant medication prior to the injury, greatly increasing the likelihood that it will have a positive impact on outcomes. Patients undergoing descending thoracic aortic (DTA) and thoracoabdominal aortic (TAA) surgery have a particularly high rate of both brain and spine ischemia. In addition, these surgeries require placement of a lumbar cerebrospinal fluid (CSF) drain, allowing access to CSF in order to monitor markers of injury and penetration of medication into the CNS. We are performing a pilot dose finding trial of prophylactic darbepoetin alfa, a long-acting erythropoiesis medication with putative neuroprotectant properties, in patients undergoing DTA and TAA surgery.
Numerous neuroprotectants have been effective when given prior to ischemic stroke in animals, yet they have all have failed when given after ischemic stroke in humans. A novel approach to ischemic neuroprotection is needed. Many patients who undergo cardiac, vascular, and neurosurgical procedures develop ischemic central nervous system (CNS) complications. These high risk surgeries present a unique opportunity to administer neuroprotectant medication prior to the injury, greatly increasing the likelihood that it will have a positive impact on outcomes. Patients undergoing descending thoracic aortic (DTA) and thoracoabdominal aortic (TAA) surgery have a particularly high rate of both brain and spine ischemia. In addition, these surgeries require placement of a lumbar cerebrospinal fluid (CSF) drain, allowing access to CSF in order to monitor markers of injury and penetration of medication into the CNS. We performed a pilot dose finding trial of prophylactic darbepoetin alfa, a long-acting erythropoiesis medication with putative neuroprotectant properties, in patients undergoing DTA and TAA surgery. This dose finding trial was stopped early after 9 patients were enrolled at the request of the FDA after an unrelated trial of erythropoietin in acute stroke performed in Germany was negative and showed possible harm in those patients who received intravenous tissue plasminogen activaor (tPA). We then enrolled 9 additional patients who did not receive any intervention in order to compare them to the patients who received darbepoetin.
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
  • Spinal Ischemia
  • Stroke
  • Neuroprotection
  • Drug: Darbepoetin alfa
    Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
    Other Name: Aranesp
  • Other: Standard care
  • Experimental: Darbepoetin
    Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
    Interventions:
    • Drug: Darbepoetin alfa
    • Other: Standard care
  • Placebo Comparator: Standard care
    No Darbepoetin
    Intervention: Other: Standard care
Messé SR, McGarvey ML, Bavaria JE, Pochettino A, Szeto WY, Cheung AT, Leitner E, Miller SW, Kasner SE. A pilot study of darbepoetin alfa for prophylactic neuroprotection in aortic surgery. Neurocrit Care. 2013 Feb;18(1):75-80. doi: 10.1007/s12028-012-9710-4.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
October 2010
July 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Are men and women between the ages of 18 - 100 years old (inclusive)
  • Require descending thoracic or thoracoabdominal aorta surgical repair
  • Can provide informed consent

Exclusion Criteria:

  • Have a traumatic aortic dissection
  • Have a baseline NIHSS > 1 or modified Rankin Scale > 1
  • Have a history of stroke or myocardial infarction within the past 30 days
  • Have a preoperative hemoglobin < 9 or > 14
  • Have a history of polycythemia vera or essential thrombocytosis
  • Have a history of hematologic malignancy
  • Have a history of arterial or venous thrombosis in the past three months
  • Have uncontrolled hypertension
  • Have active malignancy requiring treatment
  • Are receiving hemodialysis
  • Are currently using recombinant human erythropoietin or darbepoetin alfa, or have an expectation to require these medications within 30 days of surgery.
  • Have a known allergy to recombinant human erythropoietin or darbepoetin alfa
  • Are pregnant or breast-feeding. Women of childbearing potential must have a negative pregnancy test (urine pregnancy test or serum beta-HCG)
Sexes Eligible for Study: All
18 Years to 100 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00647998
DISC-001
No
Not Provided
No
Not Provided
Steven Messe, University of Pennsylvania
University of Pennsylvania
Not Provided
Not Provided
University of Pennsylvania
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP